Literature DB >> 28733283

Osmotic Compounds Enhance Antibiotic Efficacy against Acinetobacter baumannii Biofilm Communities.

Azeza Falghoush1, Haluk Beyenal2, Thomas E Besser1,3, Anders Omsland1, Douglas R Call4,3.   

Abstract

Biofilm-associated infections are a clinical challenge, in part because a hydrated matrix protects the bacterial community from antibiotics. Herein, we evaluated how different osmotic compounds (maltodextrin, sucrose, and polyethylene glycol [PEG]) enhance antibiotic efficacy against Acinetobacter baumannii biofilm communities. Established (24-h) test tube biofilms (strain ATCC 17978) were treated with osmotic compounds in the presence or absence of 10× the MIC of different antibiotics (50 μg/ml tobramycin, 20 μg/ml ciprofloxacin, 300 μg/ml chloramphenicol, 30 μg/ml nalidixic acid, or 100 μg/ml erythromycin). Combining antibiotics with hypertonic concentrations of the osmotic compounds for 24 h reduced the number of biofilm bacteria by 5 to 7 log (P < 0.05). Increasing concentrations of osmotic compounds improved the effect, but there was a trade-off with increasing solution viscosity, whereby low-molecular-mass compounds (sucrose, 400-Da PEG) worked better than higher-mass compounds (maltodextrin, 3,350-Da PEG). Ten other A. baumannii strains were similarly treated with 400-Da PEG and tobramycin, resulting in a mean 2.7-log reduction in recoverable bacteria compared with tobramycin treatment alone. Multivariate regression models with data from different osmotic compounds and nine antibiotics demonstrated that the benefit from combining hypertonic treatments with antibiotics is a function of antibiotic mass and lipophilicity (r2 > 0.82; P < 0.002), and the relationship was generalizable for biofilms formed by A. baumannii and Escherichia coli K-12. Augmenting topical antibiotic therapies with a low-mass hypertonic treatment may enhance the efficacy of antibiotics against wound biofilms, particularly when using low-mass hydrophilic antibiotics.IMPORTANCE Biofilms form a barrier that protects bacteria from environmental insults, including exposure to antibiotics. We demonstrated that multiple osmotic compounds can enhance antibiotic efficacy against Acinetobacter baumannii biofilm communities, but viscosity is a limiting factor, and the most effective compounds have lower molecular mass. The synergism between osmotic compounds and antibiotics is also dependent on the hydrophobicity and mass of the antibiotics. The statistical models presented herein provide a basis for predicting the optimal combination of osmotic compounds and antibiotics against surface biofilms communities.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter; Acinetobacter baumannii; antibiotic resistance; antibiotic treatment; biofilm; biphasic response; hypertonic; infection; osmotic agent; viscosity

Mesh:

Substances:

Year:  2017        PMID: 28733283      PMCID: PMC5601334          DOI: 10.1128/AEM.01297-17

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  39 in total

Review 1.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

2.  Acinetobacter baumannii in casualties returning from Afghanistan.

Authors:  Tammy L Stuart; Michael Mulvey; Andrew E Simor; Homer C Tien; Anthony Battad; Geoff Taylor; Joseph V Vayalumkal; Christine Weir; Marianna Ofner; Denise Gravel; Shirley Paton
Journal:  Can J Infect Control       Date:  2007

Review 3.  Biofilm-specific antibiotic tolerance and resistance.

Authors:  I Olsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-29       Impact factor: 3.267

Review 4.  Opportunistic nosocomial multiply resistant bacterial infections--their treatment and prevention.

Authors:  E Bergogne-Bérézin; D Decré; M L Joly-Guillou
Journal:  J Antimicrob Chemother       Date:  1993-07       Impact factor: 5.790

5.  The effects of hyperosmosis or high pH on a dual-species biofilm of Enterococcus faecalis and Pseudomonas aeruginosa: an in vitro study.

Authors:  S V van der Waal; L W M van der Sluis; A R Özok; R A M Exterkate; J van Marle; P R Wesselink; J J de Soet
Journal:  Int Endod J       Date:  2011-08-22       Impact factor: 5.264

6.  Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia.

Authors:  S D Aaron; W Ferris; D A Henry; D P Speert; N E Macdonald
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

7.  Conjugation of Ciprofloxacin with Poly(2-oxazoline)s and Polyethylene Glycol via End Groups.

Authors:  Martin Schmidt; Simon Harmuth; Eva Rebecca Barth; Elena Wurm; Rita Fobbe; Albert Sickmann; Christian Krumm; Joerg C Tiller
Journal:  Bioconjug Chem       Date:  2015-08-26       Impact factor: 4.774

8.  A 6 x 6 drop plate method for simultaneous colony counting and MPN enumeration of Campylobacter jejuni, Listeria monocytogenes, and Escherichia coli.

Authors:  Chin Yi Chen; Gary W Nace; Peter L Irwin
Journal:  J Microbiol Methods       Date:  2003-11       Impact factor: 2.363

9.  Characterisation of pellicles formed by Acinetobacter baumannii at the air-liquid interface.

Authors:  Yassine Nait Chabane; Sara Marti; Christophe Rihouey; Stéphane Alexandre; Julie Hardouin; Olivier Lesouhaitier; Jordi Vila; Jeffrey B Kaplan; Thierry Jouenne; Emmanuelle Dé
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

10.  Maltodextrin enhances biofilm elimination by electrochemical scaffold.

Authors:  Sujala T Sultana; Douglas R Call; Haluk Beyenal
Journal:  Sci Rep       Date:  2016-10-26       Impact factor: 4.379

View more
  7 in total

1.  Responses of Acinetobacter baumannii Bound and Loose Extracellular Polymeric Substances to Hyperosmotic Agents Combined with or without Tobramycin: An Atomic Force Microscopy Study.

Authors:  Muhammedin Deliorman; F Pinar Gordesli Duatepe; Emily K Davenport; Boel A Fransson; Douglas R Call; Haluk Beyenal; Nehal I Abu-Lail
Journal:  Langmuir       Date:  2019-06-24       Impact factor: 3.882

2.  Interplay between Amoxicillin Resistance and Osmotic Stress in Helicobacter pylori.

Authors:  Ian H Windham; D Scott Merrell
Journal:  J Bacteriol       Date:  2022-04-07       Impact factor: 3.476

3.  Mechanosensitive Channels Mediate Hypoionic Shock-Induced Aminoglycoside Potentiation against Bacterial Persisters by Enhancing Antibiotic Uptake.

Authors:  Boyan Lv; Youhui Zeng; Huaidong Zhang; Zhongyan Li; Zhaorong Xu; Yan Wang; Yuanyuan Gao; Yajuan Chen; Xinmiao Fu
Journal:  Antimicrob Agents Chemother       Date:  2021-12-13       Impact factor: 5.938

4.  Staphylococcal infection prevention using antibiotic-loaded mannitol-chitosan paste in a rabbit model of implant-associated osteomyelitis.

Authors:  Zoe L Harrison; Leslie R Pace; Madison N Brown; Karen E Beenken; Mark S Smeltzer; Joel D Bumgardner; Warren O Haggard; J Amber Jennings
Journal:  J Orthop Res       Date:  2021-02-02       Impact factor: 3.494

5.  Development of a Solid Dispersion of Nystatin with Maltodextrin as a Carrier Agent: Improvements in Antifungal Efficacy against Candida spp. Biofilm Infections.

Authors:  Carlos Benavent; Carlos Torrado-Salmerón; Santiago Torrado-Santiago
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-22

6.  Silica Particles Trigger the Exopolysaccharide Production of Harsh Environment Isolates of Growth-Promoting Rhizobacteria and Increase Their Ability to Enhance Wheat Biomass in Drought-Stressed Soils.

Authors:  Anastasiia Fetsiukh; Julian Conrad; Jonas Bergquist; Salme Timmusk
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

7.  Rapid Freezing Enables Aminoglycosides To Eradicate Bacterial Persisters via Enhancing Mechanosensitive Channel MscL-Mediated Antibiotic Uptake.

Authors:  Yanna Zhao; Boyan Lv; Fengqi Sun; Jiafeng Liu; Yan Wang; Yuanyuan Gao; Feng Qi; Zengyi Chang; Xinmiao Fu
Journal:  mBio       Date:  2020-02-11       Impact factor: 7.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.